We describe 58 adult patients with melioidosis in Cambodia (2007Cambodia ( -2010. Diabetes was the main risk factor (57%); 67% of infections occurred during the rainy season.
The Study
Melioidosis was defi ned as growth of B. pseudomallei from any clinical specimen (blood, pus, or urine). Nonfermentative gram-negative rods suspected for B. pseudomallei (wrinkled colonies, oxidase positive, polymyxin and gentamicin resistant, amoxicillin/ clavulanic acid susceptible [8] ) were identifi ed by the API 20NE system (bioMérieux, Marcy L'Etoile, France). MICs were determined with Etest (Biodisk, Solna, Sweden). Interpretive criteria were those defi ned for B. pseudomallei by the Clinical and Laboratory Standards Institute (9).
Recurrences were defi ned as the culture-confi rmed reappearance of symptoms after initial response to therapy (10) . Treatment was considered appropriate if it contained ceftazidime, a carbapenem, or amoxicillin/clavulanic acid with or without SMX/TMP. Risk factors were assessed by univariate analysis. Ethical approval was granted by the University Hospital Antwerp and the National Ethical Committee in Phnom Penh.
Seventy-one isolates of B. pseudomallei were recovered from 58 patients (mean age 49 years, range 18-73 years); 34 (59%) were men. Seasonal patterns of infection are shown in Figure 1 and geographic distribution of patients' homes (56) in Figure 2 . Melioidosis was diagnosed in 39 (67%) patients during the rainy season. In 39 patients, B. pseudomallei was recovered from blood samples, which represented 12.0% of the 328 clinically signifi cant organisms from BSIs and 1.0% of the 3,976 systemic infl ammatory response syndrome episodes during the study. In 2 patients, melioidosis was retrospectively considered a recurrence 137 and 231 days postinfection.
Fifty-four (52 initial and 2 successive) isolates were used for resistance testing ( (8) , urogenital tract (4), spleen (8) , liver (5), and psoas muscle and thyroid gland (1 each). Infection was often multifocal. Seventeen (29%) patients had shock or multiorgan failure. The median delay from symptom onset to seeking treatment was 28 days (range 1-730 days). Thirty (52%) patients died; no outcome data were available for 3 patients. Death occurred early; 19 (63%) nonsurvivors died within 1 week after admission. In univariate analysis, risk factors for death were signs of shock, multiorgan failure, or BSI and not receiving appropriate empiric therapy (Table 2) . Among the 25 survivors, 22 (88%) recovered without recurrence; the other 3 were lost to follow-up during maintenance treatment. The mean duration of follow-up was 12.8 months (range 3.5-28 months).
Treatment data were available for 53 patients; 18 (34%) received inappropriate empiric therapy; all died early. Thirty-fi ve patients received appropriate treatment; 23 patients were given ceftazidime (2 g 3×/d for >14 days) with or without SMX/TMP (30 mg/kg 2×/d), 6 received amoxicillin-clavulanic acid (875-1,000 mg 3×/d) with or without SMX/TMP, and another 6 received SMX/TMP with doxycycline (200 mg 1×/d). Twenty-three patients continued maintenance therapy, primarily SMX/TMP with or without doxycycline (22 patients). Total treatment duration ranged from 3 to 6 months.
Conclusions
Our fi ndings of melioidosis in 58 adults complement the recently published data on melioidosis in children in Cambodia (7) . A limitation of our study is its retrospective nature; a small number of patients precluded detailed study of risk factors and calculation of population-based incidence data. In addition, we have not yet studied the isolates to the genetic level. However, presently used phenotypic characteristics have been validated against molecular reference standards as accurate tools for B. pseudomallei identifi cation (8) .
Risk factors for patients and epidemiologic profi les were similar to those observed in northeastern Thailand (1, 11) . Most cases occurred during or shortly after the rainy season (May-November); diabetes mellitus was the most relevant risk factor, which is consistent with fi ndings from other regions where melioidosis is endemic (1, 11, 12) . Diabetes is quickly emerging in Cambodia and remains a diffi cult-to-treat chronic disease in poor rural settings (13) .
In this study, nearly two thirds of patients had BSI and half had pneumonia. These data are consistent with studies from Thailand and Australia, where BSI and pneumonia accounted for 46%-60% and 50%-60% of manifestations, respectively (11, 12) . Soft tissue and deep organ abscesses were also frequent. The fi nding of a spleen abscess in a melioidosis-endemic area should trigger suspicion of melioidosis.
In our study, distinguishing primary infection or reinfection from relapse was not possible, but the seasonal link suggests recent infections. The 2 recurrences in our study were probably relapses caused by insuffi cient treatment of the fi rst (unrecognized) episode, as has been described in patients in Thailand and Australia (10) . The possibility of relapse emphasizes the need for intense follow-up during and after the treatment course.
We noted a high case-fatality rate, especially among patients with BSI or pneumonia, who were in shock or had multiorgan failure, or who were receiving inappropriate empirical therapy. Potential interventions to decrease risk factors for death caused by melioidosis include improved sepsis care and ensured availability of effective drugs such as ceftazidime, carbapenems, and amoxicillin/clavulanic acid. Although we did not demonstrate resistance to any of these antimicrobial drugs, resistance can occur during therapy; follow-up blood cultures during treatment is essential (14) .
During the 19-month study, we observed a learning curve on melioidosis at several levels in the hospital. Even though melioidosis is well known in the Southeast Asian region (2) , it was unfamiliar to most clinicians and laboratory staff at the start of the study. Our fi ndings may also have an effect at the national level, especially regarding early diagnosis and treatment. Awareness must be raised among health care workers and high-risk patient groups (e.g., diabetes patients). Development of quality-assured and affordable microbiological capacity throughout the country is also crucial in the broader picture of surveillance and containment of antimicrobial drug resistance. Careful adaption of local treatment guidelines is essential and has been successful in other settings, e.g., Northern Territory, Australia (15) . Because melioidosis appears endemic to Cambodia, the public health impact of this disease warrants further research and action. 
